[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"end-stage-renal-disease-esrd\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:end-stage-renal-disease-esrd":594},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,22,0,[8,47,82,114,138,171,194,219,254,291,311,338,362,383,412,434,456,480,502,526,549,574],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100641352","effectiveness-of-subgingival-instrumentation-on-delaying-end-stage-renal-disease-among-chronic-kidney-disease-patients-100641352",false,"NCT07635797","Effectiveness of Subgingival Instrumentation on Delaying End-stage Renal Disease Among Chronic Kidney Disease Patients","Effectiveness of Subgingival Instrumentation on Delaying End-stage Renal Disease Among Chronic Kidney Disease Patients: A Non-Randomized Clinical Study","Inclusion Criteria:\n\n* Patients aged 40-70 years.\n* Type 2 diabetes mellitus with chronic kidney disease and currently on oral hypoglycaemic agents.\n* Diagnosed with Stage IV or V (eGFR between 15-20 mL\u002Fmin\u002F1.73m²).\n* Not undergoing dialysis.\n* Presence of ≥20 natural teeth.\n* Diagnosed with moderate (Stage II) (as per 2017 World Workshop classification) (Interdental CAL at site of greatest loss \\>2mm but \\\u003C5 mm in ≥ 2 non-adjacent teeth).\n* Willingness to provide written informed consent.\n\nExclusion Criteria:\n\n* Patients already undergoing haemodialysis or renal transplantation.\n* Patients on insulin therapy or taking SGLT2 inhibitors and GLP-1 receptor agonists.\n* HbA1c level \\>8 %.\n* Any Periodontal therapy within past 6 months.\n* Immunocompromised patients.\n* Any history of tobacco use.\n* Pregnant or lactating women.","ALL","40 Years","70 Years",{"count":20,"type":21},40,"ESTIMATED","INTERVENTIONAL",[24],"NA","Chronic kidney disease (CKD) and periodontitis share a bidirectional inflammatory relationship, with cytokines such as IL-6, TNF-α, and hsCRP driving progression in both conditions. Non-surgical periodontal therapy (NSPT) has shown reductions in systemic inflammatory markers with emerging evidence of improved renal function, yet robust randomized controlled trials targeting pre-dialysis stage IV-V diabetic CKD patients remain lacking. In the Indian context, where diabetes-related CKD is rapidly rising and access to dialysis is limited, there is a clear lacuna in literature regarding the effectiveness of NSPT in delaying progression to end-stage renal disease. Hence, the present non-randomized clinical study is undertaken to address this gap.",[27,28,29],"Chronic Kidney Disease","Periodontitis","End Stage Renal Disease (ESRD)",[27,31,28,32,33],"Subgingival Instrumentation","End Stage Renal Disease","Dialysis","NOT_YET_RECRUITING","2026-06-16",{"date":37,"type":38},"2026-06-18","ACTUAL",{"date":40,"type":21},"2026-07",{"date":42,"type":21},"2027-12",{"name":44,"class":45},"Postgraduate Institute of Dental Sciences Rohtak","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":16,"minAge":55,"maxAge":56,"enrollmentInfo":57,"targetDuration":4,"studyType":22,"phases":59,"briefSummary":60,"conditions":61,"keywords":64,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":81},"100604778","pivotal-study-of-the-velocity-pavf-system-100604778","NCT07153939","Pivotal Study of the Velocity™ pAVF System","Multicenter Pivotal Study of the Velocity™ Percutaneous Arterio-Venous Fistula System","VENOS-3","Inclusion Criteria:\n\n1. ESRD requiring hemodialysis access or CKD with anticipated need for hemodialysis within 6 months\n2. Cubital perforating vein diameter ⩾ 2.0 and ⩽ 5.0 mm\n3. Proximal radial artery diameter ⩾ 2.0 and ⩽ 4.0 mm\n4. Age \\> 18 years and \\\u003C 80 years\n5. Willing and competent to give written informed consent\n6. Willing and able to complete all study assessments and follow-up requirements\n\nExclusion Criteria:\n\n1. Study extremity systolic blood pressure \\\u003C 100mmHg\n2. Subjects with occlusion of the ulnar or radial artery at any level or an abnormal Allen's test\n3. Subjects with a previous ipsilateral arterio-venous graft or previous ipsilateral upper arm AVF.\n4. Distance between Cubital Perforating Vein and Proximal Radial Artery \\> 3.0 mm\n5. Cephalic vein diameter \\\u003C 2.5 mm at any point from the CPV to the axillary vein\n6. Central venous occlusion ipsilateral of the study extremity\n7. Severe calcification of the radial artery that significantly impairs ultrasound visualization (e.g., acoustic shadowing) and thus precludes safe or accurate device deployment.\n8. Evidence of active systemic infections or localized to the procedure access site within the past 7 days\n9. History or evidence of severe cardiac disease (NYHA Functional Class III or IV), myocardial infarction within six months prior to study entry, ventricular tachyarrhythmias requiring continuing treatment, or unstable angina\n10. Any contraindication to antiplatelet therapy\n11. Currently being treated with another investigational device or drug\n12. Known adverse effects to sedation and\u002For anesthesia which cannot be adequately pre-medicated\n13. Uncontrolled or poorly controlled diabetes defined as a HbA1C \\> 10%\n14. Known hypercoagulable condition, bleeding diathesis or coagulation disorder\n15. Lymphedema of the study extremity\n16. Scheduled kidney transplant within 6 months of enrollment\n17. Peripheral white blood cell count \\\u003C 1,500 cells\u002FμL or \\> 13,000 cells\u002FμL and neutrophil \\> 80%\n18. Platelet count \\\u003C 75,000 cells\u002F μL\n19. Current diagnosis of carcinoma (unless in remission \\> 1 year)\n20. Pregnant or currently breast feeding\n21. Allergies to nickel or nickel titanium alloy (NiTi) or any of the components of the Velocity Implant or Delivery System\n22. Any other medical condition that in the opinion of the investigator would put the welfare of the subject at risk or confound interpretation of the study data\n23. Investigator determines that vascular anatomy at intended index procedure site is inappropriate for use of investigational device prior to attempting needle access.","18 Years","80 Years",{"count":58,"type":21},126,[24],"This study will evaluate the Velocity Percutaneous Arteriovenous Fistula (pAVF) System, a new minimally invasive method for creating dialysis access. People with kidney failure often require dialysis, which depends on having a reliable arteriovenous fistula (AVF). Traditionally, AVFs are created with surgery, but surgery can involve incisions, longer recovery, and sometimes additional procedures before the AVF can be used.\n\nThe Velocity System is designed to create an AVF through a small puncture in the skin using a catheter-based approach, without open surgery. This pivotal study will assess how safe the procedure is and how well it works for patients who need dialysis.\n\nThe study will take place at multiple centers in the United States and will enroll adults with kidney failure who are candidates for fistula creation. Participants will undergo the Velocity procedure and then be followed closely with exams, ultrasounds, and dialysis assessments for up to five years.\n\nTaking part is voluntary. Patients may benefit from a less invasive approach to dialysis access, but the main goal is to collect information that could improve future care for people with kidney failure.",[27,62,63,29],"Hemodialysis Access","Arteriovenous Fistula",[65,66,67,68,63,69,53,70],"percutaneous AVF","pAVF","endovascular AVF","endoAVF","AVF","VENOS3","RECRUITING","2026-06-13",{"date":35,"type":38},{"date":75,"type":38},"2025-10-21",{"date":77,"type":21},"2030-09",{"name":79,"class":80},"Venova Medical","INDUSTRY",12,{"id":83,"slug":84,"hasResults":11,"nctId":85,"briefTitle":86,"officialTitle":86,"acronym":87,"eligibilityCriteria":88,"healthyVolunteers":11,"sex":16,"minAge":55,"maxAge":4,"enrollmentInfo":89,"targetDuration":4,"studyType":22,"phases":91,"briefSummary":92,"conditions":93,"keywords":96,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":105,"lastUpdatePostDateStruct":106,"startDateStruct":108,"completionDateStruct":110,"leadSponsor":112,"locationsCount":46},"100643525","dry-weight-reduction-intervention-via-extra-ultrafiltration-100643525","NCT07637110","Dry Weight Reduction Intervention Via Extra Ultrafiltration","DRIVE-UF","Inclusion Criteria:\n\n* Receiving thrice weekly in-center hemodialysis treatments for end stage kidney disease for at least four weeks and clinical suspicion of volume excess based on either:\n\n  1. Persistent hypertension defined by three consecutive pre-dialysis systolic blood pressures ≥140 mmHg or three consecutive pre-dialysis systolic blood pressures 130-140 mmHg plus use of at least two anti-hypertensive medications that can be tapered.\n\n     OR\n  2. Symptoms of congestion defined by a 12-item Kidney Modified Kansas City Cardiomyopathy Questionnaire (KM-KCCQ) score \\\u003C75.\n\n     Exclusion Criteria:\n* Age \\\u003C18 years\n* Receiving hemodialysis treatments for acute kidney injury\n* Receiving hemodialysis treatments for less than four weeks\n* Planned switch to peritoneal or home dialysis within next three months\n* Current or planned incremental hemodialysis (less than 3 treatments per week)\n* Current or planned intensive hemodialysis (four or more treatments per week)\n* Scheduled kidney transplantation\n* Major cardiovascular or bleeding event within previous 90 days\n* Receiving chemotherapy or radiation treatment for cancer\n* History of cirrhosis with ascites\n* Inability to complete 24-hour ambulatory blood pressure measurement\n* Wheelchair dependance or other inability to complete six-minute walk test\n* Pre-dialysis systolic blood pressure \\\u003C100 mmHg\n* Scheduled use of midodrine with hemodialysis treatments\n* History of non-adherence with dialysis treatments\n* Pregnancy\n* Institutionalized\n* Current or pending enrollment in hospice care\n* Inappropriate for enrollment based on investigator or nephrologist discretion",{"count":90,"type":21},120,[24],"Most patients who receive hemodialysis treatments have excess fluid in their body that has slowly built up over the course of kidney disease. This extra fluid is the main cause of high blood pressure in dialysis and leads to stress on the heart and lungs.that causes debilitating symptoms and frequent hospitalizations.\n\nThis trial will test whether a focused program of 4 or 8 weeks of extra ultrafiltration treatments can remove most of this extra fluid. We believe that getting rid of large amounts of extra fluid will result in sustained improvements in blood pressure and symptoms. Ultrafiltration is a gentler type of dialysis that removes fluid but does not clean the blood.",[94,95,29],"Fluid Accumulation","Blood Pressure Management",[97,98,99,100,101,102,103,104],"ESRD","Volume overload","Fluid accumulation","End stage renal disease","Congestion","Chronic dialysis","Blood Pressure (High)","Blood pressure management","2026-06-03",{"date":107,"type":38},"2026-06-09",{"date":109,"type":21},"2026-06",{"date":111,"type":21},"2030-11",{"name":113,"class":45},"University of Washington",{"id":115,"slug":116,"hasResults":11,"nctId":117,"briefTitle":118,"officialTitle":119,"acronym":4,"eligibilityCriteria":120,"healthyVolunteers":121,"sex":16,"minAge":55,"maxAge":56,"enrollmentInfo":122,"targetDuration":4,"studyType":22,"phases":124,"briefSummary":125,"conditions":126,"keywords":4,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":128,"lastUpdatePostDateStruct":129,"startDateStruct":131,"completionDateStruct":133,"leadSponsor":135,"locationsCount":137},"100595489","radiant-health-systems-intervention-100595489","NCT07033117","RaDIANT Health Systems Intervention","The RaDIANT Health Systems Intervention for Improving Access to Kidney Transplantation","Inclusion Criteria:\n\n* Five large transplant centers (Emory Transplant Center and Piedmont Transplant Center in Atlanta, GA; Medical University of SC; Duke University in Durham, NC; and Indiana University in Indianapolis, IN) \\~800 referring dialysis center referring to these transplant centers\n\nExclusion Criteria:\n\n* Individuals referred, initiating evaluation, and waitlisted at non-participating start centers",true,{"count":123,"type":21},14000,[24],"The overarching goal of the proposed study is to determine whether the addition of structural interventions at the health system level targeting upstream barriers in the transplant process will improve access to transplant evaluation start.",[29,127],"Kidney Disease","2026-05-22",{"date":130,"type":38},"2026-05-26",{"date":132,"type":38},"2025-10-27",{"date":134,"type":21},"2027-07-31",{"name":136,"class":45},"Indiana University",5,{"id":139,"slug":140,"hasResults":11,"nctId":141,"briefTitle":142,"officialTitle":143,"acronym":144,"eligibilityCriteria":145,"healthyVolunteers":11,"sex":146,"minAge":4,"maxAge":4,"enrollmentInfo":147,"targetDuration":4,"studyType":22,"phases":148,"briefSummary":150,"conditions":151,"keywords":158,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":163,"lastUpdatePostDateStruct":164,"startDateStruct":166,"completionDateStruct":167,"leadSponsor":169,"locationsCount":46},"100640765","phase-2-anakinra-for-the-treatment-of-postprandial-hypoglycemia-in-a-patient-with-total-gastrectomy-and-end-stage-renal-disease-100640765","NCT07580079","Anakinra for the Treatment of Postprandial Hypoglycemia in a Patient With Total Gastrectomy and End-Stage Renal Disease","Anakinra for the Treatment of Recurrent Postprandial Hypoglycemia After Total Gastrectomy in a Patient With End-Stage Renal Disease","AnPHy-ReD","This is an N-of-1 Trial, tailored-designed to a single participant.\n\n* total gastrectomy\n* severe episodes of postprandial hypoglycaemia after total gastrectomy","MALE",{"count":46,"type":21},[149],"PHASE2","Post-meal low blood sugar (postprandial hypoglycemia) is a common problem after certain stomach surgeries like gastric bypass or stomach removal. It usually happens 1 to 3 hours after eating and can cause symptoms such as tiredness, hunger, sweating, dizziness, trouble speaking, or even fainting. Right now, there is no approved medication for this condition-only a careful diet reduced in sugars and refined carbohydrates can sometimes help reduce symptoms.\n\nThe AnPHy-ReD study is a personalized research study, designed for just one patient. This patient is a 52-year-old man who has been struggling with severe post-meal low blood sugar ever since his stomach was removed due to tumor in 2017. He also has end-stage kidney disease and needs dialysis three times a week.\n\nThe study is being conducted at the Cantonal Hospital of Olten in Switzerland and lasts 10 weeks, including 24 study visits. Most of these visits will happen during the patient's regular dialysis sessions. For 6 weeks, the patient will take either the drug Anakinra or a placebo (a substance with no active ingredient), in a randomly chosen order. Neither the patient nor the doctors will know which one he is taking at any given time.\n\nDuring the study, the medical team will perform various tests, including physical check-ups and blood samples to look at sugar levels, various hormone levels and inflammation in the body. The patient will also wear a continuous glucose monitor (CGM) to track his blood sugar levels 24\u002F7. In addition, he will do several mixed meal tests-this means drinking a shake containing fats, proteins, and sugars during a study appointment to see in real time how his body processes food, with doctors measuring changes in blood sugar, hormone and inflammation markers over time. During the study duration any side effects or symptoms will be closely monitored.\n\nAt the end of the study, the team will compare the results between the times the patient took Anakinra and the times he took the placebo. This will help find out if Anakinra can reduce sharp drops in blood sugar after meals and improve his overall condition.",[152,153,154,155,156,157],"Postprandial Hypoglycemia","End-stage Renal Disease (ESRD)","Gastrectomy","Glucose Metabolism Disorders","Inflammation","Gastric Bypass Surgery",[152,159,160,161,162,156],"End-Stage Renal Disease","Anakinra","Gastric Bypass","IL-1 receptor antagonist","2026-05-05",{"date":165,"type":38},"2026-05-12",{"date":40,"type":21},{"date":168,"type":21},"2026-12",{"name":170,"class":45},"Marc Donath",{"id":172,"slug":173,"hasResults":11,"nctId":174,"briefTitle":175,"officialTitle":176,"acronym":4,"eligibilityCriteria":177,"healthyVolunteers":11,"sex":16,"minAge":55,"maxAge":4,"enrollmentInfo":178,"targetDuration":4,"studyType":22,"phases":180,"briefSummary":181,"conditions":182,"keywords":183,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":187,"lastUpdatePostDateStruct":188,"startDateStruct":189,"completionDateStruct":190,"leadSponsor":192,"locationsCount":46},"100635836","multi-site-stargraft-10401-trial-100635836","NCT07557862","Multi-Site STARgraft (10401) Trial","Multi-Site Randomized Controlled Trial of STARgraft (10401) Vascular Graft for Hemodialysis Access","Inclusion Criteria:\n\n1. The patient requires the creation of vascular access for hemodialysis secondary to a diagnosis of End-Stage Renal Disease (ESRD) and intends to use the Vascular Graft device for arteriovenous (AV) access.\n2. The patient is currently on hemodialysis or intended to begin hemodialysis within 60 days following placement of the device.\n3. Adult patients, 18 years or older.\n4. Patient has given informed consent to participate in the trial.\n5. Stated willingness to comply with all trial procedures and availability for the duration of the trial.\n6. Able to effectively communicate with trial personnel.\n7. Life expectancy judged to be at least 2 years with consideration of patient frailty.\n8. Axillary vein approximately 7 mm in diameter or greater.\n9. Brachial artery approximately 4 mm in diameter or greater.\n10. Acceptable cardiac risk level (Cardiac Output ≥ 3.5 L\u002Fmin, Pulmonary Artery Pressure ≤ 50 mmHg, and Ejection Fraction ≥ 40%).\n11. Systolic blood pressure equal to or greater than 120 mmHg.\n12. Absence of central venous stenosis downstream from implant site confirmed with ultrasound and\u002For venogram.\n\nExclusion Criteria:\n\n1. Unable or unlikely to comply with trial protocol and\u002For follow-up.\n2. Pregnancy.\n3. Previous history of peritoneal dialysis (PD) treatment within the last 2 months\n4. Central venous catheter located on same side as intended implant location.\n5. Clinical morbid obesity (BMI \\> 40).\n6. Anatomical limitations, including issues discovered intraoperatively during vessel exposure.\n7. Immunodeficiency syndrome.\n8. History of hypercoagulation or bleeding disorders.\n9. Elevated platelet count \\> 1 million per microliter of blood.\n10. History of heparin-induced thrombocytopenia syndrome (HIT).\n11. Medically confirmed stenosis or compromised valves in the veins downstream of the implant site.\n12. Inadequate arterial flow or pressure proximal to the implant site.\n13. Currently participating in another investigational drug or device trial which may clinically interfere with any endpoints of this trial.\n14. Fever greater than 38°C.\n15. Known allergic reaction to silicone.\n16. Confirmed or suspected bacterial, viral or parasitic infection within 8 weeks prior to graft implant, or ongoing symptoms.\n17. Uncontrolled or poorly controlled diabetes.\n18. History or evidence of severe cardiac disease.\n19. Any other condition which, in the judgment of the Investigator, would preclude adequate evaluation or impact patient safety or trial conduct.",{"count":179,"type":21},75,[24],"This is a multi-site, single-blind with parallel group, randomized controlled trial of Healionics STARgraft (10401) vascular graft for hemodialysis access compared with a market-leading commercially available ePTFE vascular graft (Gore Propaten Vascular Graft).",[29],[184,185,186],"Vascular access","Arteriovenous graft","Hemodialysis","2026-04-29",{"date":163,"type":38},{"date":40,"type":21},{"date":191,"type":21},"2029-06",{"name":193,"class":80},"Healionics Corporation",{"id":195,"slug":196,"hasResults":11,"nctId":197,"briefTitle":198,"officialTitle":198,"acronym":4,"eligibilityCriteria":199,"healthyVolunteers":121,"sex":16,"minAge":55,"maxAge":4,"enrollmentInfo":200,"targetDuration":4,"studyType":202,"phases":4,"briefSummary":203,"conditions":204,"keywords":209,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":210,"lastUpdatePostDateStruct":211,"startDateStruct":213,"completionDateStruct":215,"leadSponsor":217,"locationsCount":46},"100632253","calciphylaxis-in-patients-with-chronic-kidney-disease---a-study-of-the-danish-calciphylaxis-research-initiative-dancari-100632253","NCT07511283","Calciphylaxis in Patients With Chronic Kidney Disease - A Study of the Danish Calciphylaxis Research Initiative (DanCaRI)","Inclusion Criteria:\n\nCases\n\n* Age ≥18 years.\n* CKD.\n* Suspicion of calciphylaxis or newly diagnosed calciphylaxis episode. The suspicion or diagnosis of calciphylaxis is a mutual decision of the involved medical specialties (nephrologist, dermatologist, pathologist, other).\n* Ability to give informed consent.\n* Ability to participate in a clinical study as assessed by the local investigator.\n* Provides written informed consent.\n\nControls\n\n* Age ≥18 years.\n* CKD\n* Ability to give informed consent.\n* Ability to participate in a clinical study as assessed by the local investigator.\n* Provides written informed consent.\n\nHealthy reference group\n\n* Age ≥18 years.\n* Self-assessed as healthy, confirmed by local investigators at inclusion\n\nExclusion Criteria:\n\nCases\n\n\\- the calciphylaxis diagnosis becomes excluded\n\nControls - Being diagnosed with calciphylaxis\n\nHealthy controls Up to 60 years of age: eGFR below 60 ml\u002Fmin\u002F1.72m2.\n\n\\- Over 60 years of age: eGFR below the 95% confidence interval for eGFR adjusted for age (Danish Society of Nephrology references ranges)",{"count":201,"type":21},860,"OBSERVATIONAL","Calciphylaxis is a rare yet life-threatening condition involving pronounced calcification in small blood vessels of the skin.\n\nKnowledge about its underlying mechanisms and contributing risk factors remains limited. Chronic kidney disease is one of the strongest disease predictors. No evidence based effective therapy is currently available. Research on the topic is mainly hindered by the condition's rarity.\n\nThe study Calciphylaxis in patients with chronic kidney disease - A study of the Danish Calciphylaxis Research Initiative (DanCaRI) is set up to facilitate the systematic retrospective and prospective comparison of patients with chronic kidney disease and calciphylaxis to matched patients with chronic kidney disease who did not develop calciphylaxis thereby providing new knowledge that can support prevention, early detection, and new treatment approaches.",[205,206,29,207,208],"Calciphylaxis","Calcific Uremic Arteriolopathy","Chronic Kidney Diseases","Nephrogenic Calciphylaxis",[205,206,208,32,207],"2026-03-30",{"date":212,"type":38},"2026-04-06",{"date":214,"type":21},"2026-04",{"date":216,"type":21},"2040-06",{"name":218,"class":45},"Odense University Hospital",{"id":220,"slug":221,"hasResults":11,"nctId":222,"briefTitle":223,"officialTitle":224,"acronym":225,"eligibilityCriteria":226,"healthyVolunteers":11,"sex":16,"minAge":55,"maxAge":4,"enrollmentInfo":227,"targetDuration":4,"studyType":22,"phases":229,"briefSummary":230,"conditions":231,"keywords":236,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":246,"lastUpdatePostDateStruct":247,"startDateStruct":249,"completionDateStruct":250,"leadSponsor":252,"locationsCount":46},"100619739","expanded-hemodialysis-versus-high-volume-online-hemodiafiltration-for-uremic-toxin-removal-100619739","NCT07348536","Expanded Hemodialysis Versus High-Volume Online Hemodiafiltration for Uremic Toxin Removal","Impact of Expanded Hemodialysis Prescription on Global Uremic Toxin Removal Compared With High-Volume Online Hemodiafiltration: A Randomized Open-Label Crossover Study","REMOV-HDx","Inclusion Criteria:\n\n* Adults aged 18 years or older\n* End stage renal disease Receiving maintenance hemodialysis three times per week on expanded hemodialysis as part of routine care for at least 1 month\n* On dialysis treatment for more than 3 months\n* Minimal or no residual urine output (less than 100 mL per day)\n* Able and willing to provide written informed consent\n\nExclusion Criteria:\n\n* Vascular access unable to support a blood flow of at least 300 mL\u002Fmin",{"count":228,"type":21},15,[24],"People with advanced kidney disease need dialysis to remove waste products from the blood. Some of these waste products, called uremic toxins, are small, while others are medium-sized and more difficult to remove. Poor removal of these toxins may contribute to symptoms and long-term complications in patients on dialysis.\n\nTwo dialysis techniques are commonly used to improve toxin removal beyond standard hemodialysis: expanded hemodialysis (HDx) using medium cut-off membranes, and high-volume online hemodiafiltration (HV-OL-HDF). Although both techniques are effective, the best way to prescribe expanded hemodialysis-particularly the ideal treatment time-has not been clearly defined.\n\nThe purpose of this study is to compare how well different treatment times of expanded hemodialysis remove small and medium-sized uremic toxins, and to compare these results with high-volume online hemodiafiltration. Toxin removal will be evaluated using a combined measurement called the Global Removal Score, which summarizes the removal of several important waste substances.\n\nThis is a single-center, randomized, open-label, crossover study. Adults receiving maintenance hemodialysis will receive three different expanded hemodialysis sessions with different treatment durations (180, 210, and 240 minutes), followed by one session of high-volume online hemodiafiltration. Blood samples will be taken before and after each dialysis session to measure toxin levels.\n\nThe results of this study may help determine whether expanded hemodialysis with shorter or standard treatment times can achieve toxin removal similar to high-volume hemodiafiltration, which could support more personalized and practical dialysis prescriptions.",[29,232,233,234,186,235],"Chronic Kidney Disease on Hemodialysis","Renal Dialysis","Uremia; Chronic","Hemodiafiltration",[237,238,239,240,241,242,243,244,245],"Expanded hemodialysis","High-volume online hemodiafiltration","Medium cut-off dialysis membranes","Uremic toxin removal","Middle molecule clearance","Chronic kidney failure","Dialysis dose optimization","Dialysis treatment time","Global removal score","2026-03-23",{"date":248,"type":38},"2026-03-24",{"date":214,"type":21},{"date":251,"type":21},"2029-12",{"name":253,"class":45},"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran",{"id":255,"slug":256,"hasResults":11,"nctId":257,"briefTitle":258,"officialTitle":259,"acronym":4,"eligibilityCriteria":260,"healthyVolunteers":11,"sex":16,"minAge":55,"maxAge":4,"enrollmentInfo":261,"targetDuration":4,"studyType":22,"phases":263,"briefSummary":264,"conditions":265,"keywords":269,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":282,"lastUpdatePostDateStruct":283,"startDateStruct":285,"completionDateStruct":287,"leadSponsor":289,"locationsCount":46},"100605044","effect-of-a-plant-focused-diet-on-nutritional-status-in-malnourished-peritoneal-dialysis-patients-100605044","NCT07157397","Effect of a Plant-Focused Diet on Nutritional Status in Malnourished Peritoneal Dialysis Patients","Effect of Plant-Focused Diet on Nutritional Status of Malnourished Patients Undergoing Peritoneal Dialysis in a Selected Hospital Care Setting","Inclusion Criteria:\n\n* Adult outpatients (\\>18 years old), attending HTCM PD clinic visits\n* Have undergone peritoneal dialysis for at least 6 months\n* Have a serum albumin level \\\u003C40 g\u002FL\n* Have a BMI of \\\u003C 25 kg\u002Fm2\n* Have a malnutrition inflammation score (MIS) of mild, moderate or severe\n* Agreed to follow the dietary instructions based on the randomization assignment\n* Agreed to attend baseline visits and additional follow-up appointments at months 1, 3, and 6 post- randomization, either in person or via telehealth, and respond to monthly or more frequent phone calls\n\nExclusion Criteria:\n\n* Have been hospitalized for the past 3 months\n* Have ongoing infection\u002Fsepsis\n* Has undergone surgery in the past 6 months\n* Have high inflammatory diseases, malignancy, or cancer\n* Have dialysis adequacy of \\\u003C1.2 Kt\u002FV",{"count":262,"type":21},100,[24],"The goal of this clinical trial is to determine whether a plant-focused diet improves nutritional and health outcomes of malnourished adults undergoing peritoneal dialysis (PD). It will also learn about the safety of this diet in this population.\n\nThe main questions it aims to answer are:\n\n1. Does a plant-focused diet improve nutritional status compared to a standard kidney diet in PD patients?\n2. What changes occur in anthropometric, biochemical, and dietary measures over 6 months?\n\nResearchers will compare the plant-focused diet to a standard-of-care renal diet to see which is more effective in improving nutrition in PD patients.\n\nParticipants will:\n\n* Be randomly assigned to follow the plant-focused diet or the standard diet.\n* Be monitored for 6 months through in-person visits (aligned with their routine clinic appointments) and virtual check-ins via messages or calls.\n* Have their progress monitored for changes in outcomes such as nutrition, blood tests, kidney function, and quality of life.",[29,266,267,268],"End Stage Kidney Disease (ESRD)","Peritoneal Dialysis (PD)","Malnourished",[270,32,271,272,273,274,275,276,277,278,156,279,280,281],"Peritoneal Dialysis","End Stage Kidney Disease","Malnutrition","Plant-Focused Diet","Plant-Based Diet","Nutritonal Status","Dietary Counselling","Quality of Life","Physical Fitness","Appetite","Malaysia","Nutritional Intervention","2026-03-12",{"date":284,"type":38},"2026-03-16",{"date":286,"type":38},"2026-03-10",{"date":288,"type":21},"2027-03-31",{"name":290,"class":45},"National University of Malaysia",{"id":292,"slug":293,"hasResults":11,"nctId":294,"briefTitle":295,"officialTitle":295,"acronym":4,"eligibilityCriteria":296,"healthyVolunteers":11,"sex":16,"minAge":55,"maxAge":4,"enrollmentInfo":297,"targetDuration":4,"studyType":202,"phases":4,"briefSummary":299,"conditions":300,"keywords":301,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":302,"lastUpdatePostDateStruct":303,"startDateStruct":305,"completionDateStruct":307,"leadSponsor":308,"locationsCount":310},"100604233","endoforce-post-approval-study-100604233","NCT07146854","EndoForce Post Approval Study","Inclusion Criteria:\n\n* Patient is ≥18 years of age.\n* Patient requires the creation of a vascular access graft for hemodialysis, secondary to a diagnosis of ESRD.\n* Patient is able to have the vascular access ePTFE graft placed in an upper arm.\n* Patient or his\u002Fher legal guardian understands the study and is willing and able to comply with the dialysis schedule and follow-up requirements.\n* Patient or his\u002Fher legal guardian provides written informed consent.\n\nExclusion Criteria:\n\n* All contraindications for the EndoForce Connector System according to the IFU.\n* Patient is pregnant.\n* Patient is enrolled in another dialysis or vascular investigational study, without prior approval from the Sponsor.",{"count":298,"type":21},150,"The goal of this observational study is to collect long-term safety and performance data for the use of the EndoForce System for connecting a hemodialysis graft to a vein in patients with End Stage Renal Disease. This is not an experimental procedure or an experimental therapy. This means that the study device has been approved by the FDA.",[29],[186,185],"2026-01-16",{"date":304,"type":38},"2026-01-21",{"date":306,"type":38},"2026-01-13",{"date":251,"type":21},{"name":309,"class":80},"Phraxis, Inc.",2,{"id":312,"slug":313,"hasResults":11,"nctId":314,"briefTitle":315,"officialTitle":316,"acronym":317,"eligibilityCriteria":318,"healthyVolunteers":11,"sex":16,"minAge":319,"maxAge":320,"enrollmentInfo":321,"targetDuration":4,"studyType":22,"phases":323,"briefSummary":324,"conditions":325,"keywords":4,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":328,"lastUpdatePostDateStruct":329,"startDateStruct":331,"completionDateStruct":333,"leadSponsor":335,"locationsCount":46},"100620709","a-comparative-study-of-intradialytic-vs-pre-dialysis-physical-therapy-interventions-in-individuals-undergoing-hemodialysis-a-randomized-controlled-trial-100620709","NCT07361146","A Comparative Study of Intradialytic vs. Pre-Dialysis Physical Therapy Interventions in Individuals Undergoing Hemodialysis: A Randomized Controlled Trial","A Comparative Study of Intradialytic Versus Pre-Dialysis Physical Therapy Interventions in Individuals Undergoing Hemodialysis: A Randomized Controlled Trial","DIAL-PT","Inclusion Criteria:\n\n* Adults aged between 21 and 65 years.\n* Diagnosed with end-stage renal disease (ESRD).\n* Undergoing maintenance hemodialysis for at least 3 months.\n* Medically stable and cleared by the nephrologist to participate in moderate physical exercise.\n* Able to understand and follow verbal instructions and provide informed consent.\n\nExclusion Criteria:\n\n* Uncontrolled hypertension, recent myocardial infarction, or unstable angina.\n* Severe musculoskeletal, neurological, or cardiovascular disorders that limit physical activity.\n* Active infection, fever, or open wounds.\n* Recent hospitalization within the past month.\n* Participation in any other structured exercise program within the last 3 months.","21 Years","65 Years",{"count":322,"type":21},72,[24],"This randomized controlled trial aims to compare the effectiveness of two different timings of physical therapy for individuals undergoing hemodialysis: intradialytic (during dialysis) and pre-dialysis (before dialysis). The study seeks to determine which approach provides better improvements in physical function, quality of life, and biochemical outcomes such as hemoglobin and electrolyte levels.\n\nA total of 72 adult participants with end-stage renal disease (ESRD) receiving hemodialysis will be randomly assigned to one of two groups. Both groups will receive standardized educational sessions on the benefits and safety of exercise before beginning the intervention. Participants in the intradialytic group will perform supervised exercises during their dialysis sessions, while those in the pre-dialysis group will complete similar exercises before their dialysis sessions. Each participant will undergo the intervention twice per week for 12 weeks.\n\nPrimary outcomes include physical function, assessed using the Six-Minute Walk Test and the Five Times Sit-to-Stand Test. Secondary outcomes include hemoglobin levels, electrolyte balance, and health-related quality of life measured by the KDQOL questionnaire. The study will be conducted at Mubarak Al-Abdullah Al-Jaber Al-Sabah Dialysis Center, Kuwait, following ethical approval from the Ministry of Health Research Ethics Committee.\n\nThe results are expected to inform best practices for integrating physical therapy into dialysis care to enhance the health, safety, and well-being of individuals undergoing hemodialysis.",[153,27,326,327],"Hemodialysis Patients","Physical Rehabilitation During Dialysis","2026-01-14",{"date":330,"type":38},"2026-01-22",{"date":332,"type":38},"2025-03-02",{"date":334,"type":21},"2027-06-02",{"name":336,"class":337},"Mohammad Arian","OTHER_GOV",{"id":339,"slug":340,"hasResults":11,"nctId":341,"briefTitle":342,"officialTitle":342,"acronym":4,"eligibilityCriteria":343,"healthyVolunteers":11,"sex":16,"minAge":55,"maxAge":344,"enrollmentInfo":345,"targetDuration":4,"studyType":22,"phases":347,"briefSummary":348,"conditions":349,"keywords":4,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":352,"lastUpdatePostDateStruct":353,"startDateStruct":355,"completionDateStruct":357,"leadSponsor":359,"locationsCount":361},"100414067","a-study-to-evaluate-the-safety-and-effectiveness-of-the-innavasc-arteriovenous-graft-for-hemodialysis-access-in-patients-with-end-stage-renal-disease-100414067","NCT04671771","A Study to Evaluate the Safety and Effectiveness of the InnAVasc Arteriovenous Graft for Hemodialysis Access in Patients With End-Stage Renal Disease","Inclusion Criteria:\n\nPre-Operative Inclusion Criteria:\n\nPatients must meet the following criteria at screening in order to be scheduled for a procedure and potentially enrolled in the study:\n\n1. Patients with ESRD whose next most appropriate option for AV access is placement of an AV graft to start or maintain hemodialysis therapy;\n2. Age 18 to 90 years old, inclusive;\n3. Suitable anatomy for implantation of upper arm \"straight\" or looped graft, or forearm looped graft (graft not to cross the bend of the elbow);\n4. Ability to continue or commence antiplatelet therapy post graft implant (anticoagulation medication is acceptable if the subject is required to take an anticoagulant for a baseline medical condition);\n5. Able and willing to give informed consent;\n6. Anticipated life expectancy of at least 1 year.\n\nIntra-Operative Inclusion Criteria:\n\nBoth vessels have been exposed and are deemed appropriate for implantation (i.e., based on the surgeon's opinion, artery is of adequate size, has adequate pulse to support AV access flow, is without significant calcification, and is safely clampable; and the vein is of adequate size, free of localized sclerosis, and is free of immediate outflow obstruction).\n\nPre-Operative Exclusion Criteria:\n\nPatients will be excluded from the study at screening if they exhibit any of the following exclusion criteria:\n\n1. History or evidence of severe cardiac disease (i.e., debilitating heart failure, or high risk of MI) in the opinion of the investigator which may preclude participation in and completion of the study;\n2. Uncontrolled diabetes in the opinion of the investigator (i.e., multiple recent diabetes related hospitalizations);\n3. For upper arm straight configuration, an antecubital fossa crease to axillary crease distance \\\u003C 18 cm;\n4. History or evidence of severe peripheral arterial disease in the extremity selected for implant (i.e., arterial inflow insufficient to support hemodialysis access);\n5. Known or suspected central vein stenosis or obstruction on the side of planned graft implantation;\n6. Baseline hypotension or history of frequent hypotensive episodes during dialysis that, in the opinion of the investigator, puts the patient at increased risk of graft thrombosis;\n7. Uncontrolled hypertension, per the opinion of the investigator (i.e., recent history of recurrent hospitalizations for hypertensive related illness);\n8. Baseline hemoglobin \\\u003C7 g\u002FdL;\n9. Baseline platelet count \\\u003C50,000 or \\>500,000 cells\u002Fmm3;\n10. Documented history of stroke within 6 months prior to enrollment;\n11. Treatment with any investigational drug or device within 30 days prior to enrollment;\n12. Female patients who are pregnant, intending to become pregnant, nursing or intending to breastfeed during the study (pregnancy test may only be omitted, if patient is post-menopausal or has a documented history of hysterectomy or permanent sterilization);\n13. History of cancer with active disease or treatment within the previous year, except for non-invasive basal or squamous cell carcinoma of the skin;\n14. Immunodeficiency including documented history of human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS) or patients receiving immunosuppressive therapy for treatment of an acute inflammatory event or autoimmune flare. Chronic immunosuppressive therapy is acceptable;\n15. Documented or suspected hypercoagulable condition;\n16. Bleeding diathesis, other than that associated with ESRD;\n17. Documented history of heparin-induced thrombocytopenia (HIT);\n18. Active local or systemic infection as documented from the medical history or bloodwork\u002Fblood culture data. If the infection resolves, the subject must be at least one-week post resolution of that infection before implantation;\n19. Scheduled renal transplant within 6 months;\n20. Any other condition which in the judgment of the investigator would preclude adequate evaluation of the safety and effectiveness of the IG;\n21. Patient is unable or unwilling to complete all required follow-up assessments and questionnaires.","90 Years",{"count":346,"type":21},133,[24],"The goal of the CSP-2002 clinical trial is to evaluate the safety and effectiveness of the InnAVasc Arteriovenous Graft (IG) for hemodialysis (HD) access in patients with end-stage renal disease (ESRD). The primary study endpoints are:\n\nPrimary Effectiveness Endpoint: The proportion of subjects with secondary patency at 6 months.\n\nPrimary Safety Endpoint: The incidence of device-related adverse events of special interest (AESIs) through 6 months.\n\nParticipants will be asked to sign an informed consent form. Once enrolled, they will be assessed to receive the study graft implant and asked to participate in periodic follow-up visits and assessments through 2 years following implant.",[29,350,351,186],"Kidney Failure","Chronic Renal Disease","2025-12-18",{"date":354,"type":38},"2025-12-22",{"date":356,"type":38},"2020-12-03",{"date":358,"type":21},"2029-07-01",{"name":360,"class":80},"W.L.Gore & Associates",21,{"id":363,"slug":364,"hasResults":11,"nctId":365,"briefTitle":366,"officialTitle":366,"acronym":4,"eligibilityCriteria":367,"healthyVolunteers":11,"sex":16,"minAge":55,"maxAge":368,"enrollmentInfo":369,"targetDuration":4,"studyType":22,"phases":371,"briefSummary":372,"conditions":373,"keywords":4,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":375,"lastUpdatePostDateStruct":376,"startDateStruct":377,"completionDateStruct":379,"leadSponsor":381,"locationsCount":46},"100615326","impact-of-app-assisted-patient-management-on-the-quality-control-of-blood-purification-therapy-100615326","NCT07291154","Impact of APP-assisted Patient Management on the Quality Control of Blood Purification Therapy","Inclusion Criteria:\n\n* Patients with stage 5 chronic kidney disease, who have received maintenance hemodialysis for more than 3 months, are aged between 18 and 75 years old, and have regular dialysis three times a week.\n* Patients with relatively stable condition, who are able to take care of themselves and willing to cooperate with the study.\n* Patients who can understand and proficiently use WeChat and the \"Yueya\" mini - program used in this study.\n\nExclusion Criteria:\n\n* Patients with communication barriers or other conditions that prevent them from cooperating with the study.\n* Patients who have a history of acute myocardial infarction, cerebral infarction or intracerebral hemorrhage in the past six months.\n* Patients who are not willing to actively cooperate with the study.\n* Patients with severe liver cirrhosis, active tuberculosis and AIDS.","75 Years",{"count":370,"type":21},392,[24],"Many maintenance hemodialysis (MHD) patients develop negative outlooks due to their illnesses and complications, making their quality of life and prognosis a clinical concern. Effective life management and treatment cooperation are crucial to improving dialysis quality and patient outcomes. This trial aims to evaluate whether management through the \"Yueya\" mini-program and WeChat can provide personalized guidance such as health education, diet, exercise, medication supervision, and condition monitoring to enhance treatment compliance, quality of life, strengthen quality control in the hemodialysis unit, and improve patient prognosis.\n\nPatients will be divided into a group receiving support via the \"Yueya\" mini-program and WeChat, and a control group receiving routine care. Clinical and laboratory indicators, cardiovascular events, death, hospitalization, quality of life, and compliance will be recorded and compared between groups to assess the impact of APP-assisted patient management on the quality of MHD blood purification therapy and the prognosis of MHD patients.",[29,374],"Maintenance Hemodialysis","2025-12-05",{"date":352,"type":38},{"date":378,"type":38},"2025-09-22",{"date":380,"type":21},"2026-12-31",{"name":382,"class":45},"Yunfeng Xia",{"id":384,"slug":385,"hasResults":11,"nctId":386,"briefTitle":387,"officialTitle":388,"acronym":389,"eligibilityCriteria":390,"healthyVolunteers":11,"sex":16,"minAge":55,"maxAge":4,"enrollmentInfo":391,"targetDuration":4,"studyType":22,"phases":392,"briefSummary":393,"conditions":394,"keywords":397,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":404,"lastUpdatePostDateStruct":405,"startDateStruct":407,"completionDateStruct":409,"leadSponsor":410,"locationsCount":46},"100608820","effect-of-modifying-magnesium-concentration-in-citrate-enriched-dialysate-on-hemodialysis-associated-thromboinflammation-100608820","NCT07206524","Effect of Modifying Magnesium Concentration in Citrate-enriched Dialysate on Hemodialysis-associated Thromboinflammation","Effect of Modifying Magnesium Concentration in Citrate-enriched Dialysate on Hemodialysis-associated Thromboinflammation: a Local Pilot OMAGOD Plus Trial","pilot OMAGOD +","Inclusion Criteria:\n\n* Participants to the OMAGOD pilot trial\n\nExclusion Criteria:\n\n* Patients who are not participating in the OMAGOD pilot trial",{"count":228,"type":21},[24],"This clinical trial investigates whether the composition of dialysate influences hemodialysis-associated thromboinflammation. Specifically, it evaluates the effects of magnesium concentration and acid type in dialysate on immune cell activation and thromboinflammatory responses.\n\nPatients participating to the multicentric pilot OMAGOD trial will be invited to participate to this monocentric plus study.\n\nIn the pilot OMAGOD trial, participants will undergo standard hemodialysis (3 sessions\u002Fweek, 4 hours each) and receive three different dialysate compositions in a crossover design. Each treatment phase lasts two weeks (six sessions).\n\nFor the local plus study, during selected sessions (3 per patient - midweek hemodialysis session of the last week of a treatment period), blood samples will be collected (at baseline, hourly, and at the end of dialysis) and additionally, after each session, the used dialysis circuit will be rinsed to recover adherent cells.\n\nThe study aims to:\n\n* Assess whether the dialysate composition influences leukocyte and platelet activation .\n* Evaluate whether the dialysate composition influences neutrophil extracellular trap (NET) formation.\n* Identify novel biomarkers of thromboinflammation using transcriptomic analysis of immune cells.",[186,395,396,29],"Thromboinflammation","Hemodialysis Complication",[398,399,400,401,402,403],"hemodialysis","thromboinflammation","neutrophil extracellular trap formation","dialysate composition","cellular activation","transcriptome analysis","2025-11-14",{"date":406,"type":38},"2025-11-17",{"date":408,"type":38},"2025-06-05",{"date":168,"type":21},{"name":411,"class":45},"Universitair Ziekenhuis Brussel",{"id":413,"slug":414,"hasResults":11,"nctId":415,"briefTitle":416,"officialTitle":417,"acronym":4,"eligibilityCriteria":418,"healthyVolunteers":11,"sex":16,"minAge":55,"maxAge":419,"enrollmentInfo":420,"targetDuration":4,"studyType":202,"phases":4,"briefSummary":422,"conditions":423,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":425,"lastUpdatePostDateStruct":426,"startDateStruct":428,"completionDateStruct":430,"leadSponsor":432,"locationsCount":4},"100609162","prevalence-of-latent-tuberculosis-infection-among-hemodialysis-patients-100609162","NCT07210970","Prevalence of Latent Tuberculosis Infection Among Hemodialysis Patients","Study of The Prevalence of Latent Tuberculosis Infection Among Hemodialysis Patients Using Tuberculin Skin Test at Sohag University Hospital","Inclusion Criteria:\n\nAge ≥ 18 years Patients on regular hemodialysis Able and willing to provide informed consent\n\n\\-\n\nExclusion Criteria:\n\n* active TB patients","100 Years",{"count":421,"type":21},200,"This observational cross-sectional study aims to determine the prevalence of latent tuberculosis infection (LTBI) among patients undergoing regular hemodialysis at Sohag University Hospital, using the tuberculin skin test (TST). Identifying the burden of LTBI in this high-risk population will help guide early detection and preventive strategies",[424,29,186],"Latent Tuberculosis Infection","2025-09-30",{"date":427,"type":38},"2025-10-07",{"date":429,"type":21},"2025-12-01",{"date":431,"type":21},"2027-12-20",{"name":433,"class":45},"Sohag University",{"id":435,"slug":436,"hasResults":11,"nctId":437,"briefTitle":438,"officialTitle":439,"acronym":4,"eligibilityCriteria":440,"healthyVolunteers":11,"sex":16,"minAge":55,"maxAge":4,"enrollmentInfo":441,"targetDuration":4,"studyType":22,"phases":442,"briefSummary":443,"conditions":444,"keywords":4,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":447,"lastUpdatePostDateStruct":448,"startDateStruct":450,"completionDateStruct":452,"leadSponsor":454,"locationsCount":46},"100585784","phase-2-activated-charcoal-use-in-chronic-kidney-disease-patients-100585784","NCT06906874","Activated Charcoal Use in Chronic Kidney Disease Patients","Efficacy and Safety of Activated Charcoal on Mineral Bone Disorder in Chronic Kidney Disease Patients","Inclusion Criteria:\n\n1. Adult aged ≥18 years with ESRD.\n2. Patients who had been on stable maintenance hemodialysis (3 times weekly) for at least 6 months.\n3. Patients receiving phosphate binders according to standard protocols established by kidney disease: Improving Global Outcomes (KDIGO).\n\nExclusion Criteria:\n\n1. Severely malnourished (as diagnosed by the department's dietitian).\n2. Treated with overnight dialysis.\n3. Primary hyperparathyroidism or persistent serum levels of intact parathyroid hormone greater than 800 pg\u002FmL.",{"count":20,"type":21},[149],"Hyperphosphatemia management is initially based on restricting dietary phosphorus intake. Hyperphosphatemia is almost always seen in patients on dialysis and may contribute to progressive vascular calcification. Considering that activated charcoal is generally well-tolerated and may have a favorable side effect profile compared to conventional phosphate binders, it presents a promising alternative. Until now, no clinical trial has primarily investigated the effect of activated charcoal on hyperphosphatemia in dialysis patients.",[29,445,446],"CKD 5D, Hemodialysis","CKD-MBD - Chronic Kidney Disease Mineral and Bone Disorder","2025-08-05",{"date":449,"type":38},"2025-08-08",{"date":451,"type":21},"2025-08",{"date":453,"type":21},"2025-11",{"name":455,"class":45},"Mansoura University",{"id":457,"slug":458,"hasResults":11,"nctId":459,"briefTitle":460,"officialTitle":461,"acronym":4,"eligibilityCriteria":462,"healthyVolunteers":121,"sex":16,"minAge":463,"maxAge":4,"enrollmentInfo":464,"targetDuration":4,"studyType":202,"phases":4,"briefSummary":465,"conditions":466,"keywords":467,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":471,"lastUpdatePostDateStruct":472,"startDateStruct":474,"completionDateStruct":476,"leadSponsor":478,"locationsCount":46},"100582867","rheological-functions-of-erythrocyte-in-esrd-100582867","NCT06868888","Rheological Functions of Erythrocyte in ESRD","The Effect of Osmotic Stress in Erythrocyte Rheology in ESRD Patients","Inclusion Criteria:\n\n* Receiving hemodialysis and medication at least for 6 weeks\n* Kt\u002FV score \\> 1.2\n\nExclusion Criteria:\n\n* Under 20 years-old\n* Hyperkalemia occurs within 3 month\n* Having orthopedic or muscular diseases\n* Other concerned medical, psychological or physiological diseases\n* Pregnancy\n* Other exercise contraindications","20 Years",{"count":20,"type":21},"End-stage renal disease (ESRD) disrupts erythrocyte deformability due to osmotic imbalances, oxidative stress, and uremic toxins, leading to impaired microcirculation and oxygen transport. Dysregulation of ion channels, particularly the Gardos channel, exacerbates dehydration and eryptosis, further compromising vascular integrity. Given the critical role of erythrocyte flexibility in oxygen delivery, this study investigates its relationship with aerobic capacity in ESRD patients, highlighting potential mechanisms of microvascular dysfunction",[153],[186,468,469,470],"Aerobic capacity","Deformability","Erythrocyte","2025-03-05",{"date":473,"type":38},"2025-03-11",{"date":475,"type":38},"2022-08-24",{"date":477,"type":21},"2025-03-26",{"name":479,"class":45},"Chang Gung Memorial Hospital",{"id":481,"slug":482,"hasResults":11,"nctId":483,"briefTitle":484,"officialTitle":485,"acronym":4,"eligibilityCriteria":486,"healthyVolunteers":11,"sex":16,"minAge":55,"maxAge":368,"enrollmentInfo":487,"targetDuration":4,"studyType":202,"phases":4,"briefSummary":489,"conditions":490,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":493,"lastUpdatePostDateStruct":494,"startDateStruct":496,"completionDateStruct":498,"leadSponsor":500,"locationsCount":46},"100580555","cgm-in-icodextrin-pd-100580555","NCT06838819","CGM in Icodextrin PD","Evaluation of Accuracy of Medtronic Simplera™ CGM in Patients on Icodextrin-containing Peritoneal Dialysis Regimens","Inclusion Criteria:\n\n1. Type 1 or 2 diabetes mellitus for at least 3 months\n2. On continuous ambulatory peritoneal dialysis (CAPD) or APD for at least 2 months\n3. On icodextrin PD solutions for at least 1 month or planned for switching to icodextrin PD solutions within 3 months of screening\n4. Male or female age ≥ 18 years old and ≤ 75 year old.\n5. Women who are not pregnant, lactating or planning a pregnancy during their participation in the clinical study.\n6. Willingness, ability and commitment to comply with the testing, procedure and follow-up outlined in this protocol including (but not limited to) frequency of clinic visits and use of pre-specified glucose monitoring devices.\n7. Willingness to abstain from swimming during their participation in the measurement phase.\n8. In the opinion of the investigator, absence of any physical limitations, addictive diseases, or underlying medical conditions (including mental health) that may preclude the patient from being a good study candidate.\n9. Written informed consent to participate in the study provided by the patient.\n\nExclusion Criteria:\n\n1. Poorly controlled diabetes mellitus with HbA1c\\>11%\n2. Peritonitis within 1 month of screening\n3. Planned for switching to hemodialysis or living donor transplant in the future 1 month\n4. Currently pregnant, as demonstrated by a positive pregnancy test at screening for women of reproductive potential\n5. Any active acute or chronic disease or condition that, in the opinion of the investigator, might interfere with the performance of this study.\n6. Any active acute or chronic infectious disease that, in the opinion of the investigator, would pose an excessive risk to study staff.\n7. Current use or recent exposure to any medication that in the opinion of the investigator could have an influence on the patient's ability to participate in this study or on the performance of the test device.\n8. Extensive skin changes\u002Fdiseases that preclude wearing the required number of devices on normal skin at the proposed application sites (e.g., extensive psoriasis, recent burns or severe sunburn, extensive eczema, extensive scarring, extensive tattoos, dermatitis herpetiformis).\n9. Have a known allergy to medical-grade adhesives, or known hypersensitivity to any of the products used in the study.\n10. Blood donation of more than 500 ml within the last three months\n11. Currently participating in another investigational study protocol where the testing or results may interfere with study compliance, diagnostic results, or data collection.\n12. Has a MRI scan, CT scan, or diathermy scheduled during the proposed study participation.\n13. An identified protected vulnerable patient (including but not limited to those in detention, or a prisoner).\n14. Women of reproductive potential who are unwilling to adopt contraceptive measures during the study period\n15. Patients with history of pacemaker and prosthesis implantation.\n16. Continuous use of real-time CGM for personal diabetes management in the three months prior to screening (sensor use \\>80% of time)",{"count":488,"type":21},30,"Assessment of performance (precision and accuracy) of Simplera™ CGM as compared with a gold standard reference laboratory method (YSI glucose) in diabetes patients on peritoneal dialysis with icodextrin",[491,29,33,492],"Diabetes Mellitus (Diagnosis)","Continuous Glucose Monitoring","2025-02-17",{"date":495,"type":38},"2025-02-21",{"date":497,"type":21},"2025-02-20",{"date":499,"type":21},"2026-09-20",{"name":501,"class":45},"Elaine Chow",{"id":503,"slug":504,"hasResults":11,"nctId":505,"briefTitle":506,"officialTitle":507,"acronym":508,"eligibilityCriteria":509,"healthyVolunteers":11,"sex":16,"minAge":55,"maxAge":4,"enrollmentInfo":510,"targetDuration":4,"studyType":22,"phases":511,"briefSummary":513,"conditions":514,"keywords":515,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":518,"lastUpdatePostDateStruct":519,"startDateStruct":520,"completionDateStruct":522,"leadSponsor":524,"locationsCount":46},"100580354","phase-1-the-effect-of-gum-arabic-ga-on-residual-renal-function-in-adult-dialysis-patients-in-abu-dhabi-100580354","NCT06836206","The Effect of Gum Arabic (GA) on Residual Renal Function in Adult Dialysis Patients in Abu Dhabi","The Effect of Gum Arabic (GA) on Adult Dialysis Patients in Abu Dhabi: A Prospective Randomized-controlled Trial (The GADAD Study)","GAESRD","Inclusion Criteria:\n\nTo be eligible to participate in this trial, an individual must meet all the following criteria:\n\n1. Men and women ≥18 years of age with diagnosed ESRD and prescribed regular dialysis at least once a week, weekly at least for past two weeks.\n2. For past two weeks including women of childbearing potential who are currently adopting any method of contraception or have completed the family and undergone sterilization procedures and women of non-childbearing potential.\n3. Patients with residual renal function - Patients who produce a minimum of 200 ml of urine during a full day of collection (A full day collection: the patient discards the first urine sample on the day of collection then collects all urine for the entire day and night and collects the first urine sample of the next day) r on a non-dialysis long break day.\n4. Able and willing to complete the whole period of the study (maximum of 266 days from enrolment).\n5. With the ability to understand the study procedures, the informed consent \\& voluntarily sign an informed consent form and be able to comply with the requirements of the protocol.\n\nExclusion Criteria:\n\n1. Women of childbearing potential not adopting any methods of contraception, have not undergone sterilization.\n2. Women Pregnant or lactating\n3. Patients who plan to conceive (or for their partners to conceive) within 12 months of randomization.\n4. Patient presenting with serum K+levels ≥ 6mmol\u002FL based on the last two reports as per medical records.\n5. Patients who produce less than 200 ml of urine during 24 hours urine collection at baseline assessment.\n6. Peritoneal dialysis.\n7. Kidney transplant or booked for a live transplant within 259 days of randomization.\n8. Patients gaining \\>4 kg between dialysis sessions in the past 2 weeks.\n9. People with known allergies to quillaja bark or similar tree bark.\n10. Patients are already participating in another clinical trial (excluding COVID-19 vaccine or COVID-19 drug trials).\n11. Patients on immunosuppression for kidney transplant.\n\nAdditional exclusion criteria for follow-up visits.\n\n1. Patient informs of pregnancy.\n2. Severe adverse reaction to the interventional product.",{"count":20,"type":21},[512,149],"PHASE1","Gum Arabic (GA), derived from Acacia trees, has shown potential benefits in metabolic, renal, and inflammatory conditions. This study explores the impact of GA on residual renal function in end-stage renal disease (ESRD) patients undergoing dialysis, as current evidence is limited.",[29],[516,97,517],"Gum Arabic","Acacia seyal and Acacia senegal","2025-02-14",{"date":497,"type":38},{"date":521,"type":38},"2025-02-03",{"date":523,"type":21},"2026-04-30",{"name":525,"class":337},"Abu Dhabi Health Services Company",{"id":527,"slug":528,"hasResults":11,"nctId":529,"briefTitle":530,"officialTitle":531,"acronym":4,"eligibilityCriteria":532,"healthyVolunteers":11,"sex":16,"minAge":55,"maxAge":4,"enrollmentInfo":533,"targetDuration":4,"studyType":202,"phases":4,"briefSummary":534,"conditions":535,"keywords":537,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":540,"lastUpdatePostDateStruct":541,"startDateStruct":543,"completionDateStruct":545,"leadSponsor":547,"locationsCount":4},"100575414","ultrasound-prediction-of-successful-balloon-assisted-avf-maturation-100575414","NCT06771973","Ultrasound Prediction of Successful Balloon Assisted AVF Maturation","A Prospective Cohort Study Analysing Prediction of Successful Arteriovenous Fistula (AVF) Maturation Post Balloon Assisted Fistuloplasty With Duplex Ultrasound and Inflammatory Biomarkers","Inclusion Criteria:\n\n* Adult patients (\\>18 years of age) referred for BAM procedure due to immature native AVF\n* AVFs with radio-cephalic or brachio-cephalic configuration\n* AVF suitable for endovascular BAM procedure\n* Patient is able to provide informed consent\n* Patient is willing and able to comply with the study-related procedures\n\nExclusion Criteria:\n\n* Brachio-basilic AVFs requiring transposition and superficialisation procedures during maturation phase\n* Patients with arterio-venous grafts (AVGs) for vascular access\n* Previous BAM procedures performed to facilitate maturation\n* AVF unsuitable for BAM procedure or BAM procedure not performed",{"count":20,"type":21},"An arteriovenous fistula (AVF) is created to allow for cleaning of the blood in patients with severe kidney disease. An artery and a vein are surgically connected, typically in the arm. This connection changes how the blood flows through the vessels, creating much higher flow in the arm vein than before the operation. Higher blood flow enables blood flow to be cleaned externally with a machine replacing the function of the kidneys. This process is known as dialysis. However, a period known as maturation is required before an AVF can be used in this way. During this time, the vessels grow in size and blood flow continues to increase. In some cases this does not happen and a procedure is required to help the AVF to mature.\n\nAVFs not likely to mature may undergo a procedure, known as balloon assisted maturation (BAM), in which a balloon on the end of a catheter is inserted into the AVF vein and inflated. This is typically needed if an AVF is not likely to develop in a way that can be used for dialysis. Blood cleaning, or haemodialysis, is vital in patients with end stage renal disease, or kidney failure. Blood flow measurement using ultrasound, and routine blood test results, may help us predict which AVFs will respond better to BAM. Ultrasound can be used in the clinic setting and can provide the consultants responsible for the patients ongoing management with information that can enable decisions to be made at an early opportunity, and allowing the participants to be involved in future management decisions. This study aims to identify features of the blood flow following the BAM procedure that might be used to predict if the AVF will successfully mature.",[29,536],"Chronic Kidney Disease Requiring Hemodialysis",[538,69,539,97],"arteriovenous fistula","CKD","2025-01-14",{"date":542,"type":38},"2025-01-15",{"date":544,"type":21},"2025-01-13",{"date":546,"type":21},"2026-04-01",{"name":548,"class":45},"Guy's and St Thomas' NHS Foundation Trust",{"id":550,"slug":551,"hasResults":11,"nctId":552,"briefTitle":553,"officialTitle":554,"acronym":4,"eligibilityCriteria":555,"healthyVolunteers":11,"sex":16,"minAge":55,"maxAge":368,"enrollmentInfo":556,"targetDuration":4,"studyType":22,"phases":558,"briefSummary":560,"conditions":561,"keywords":562,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":565,"lastUpdatePostDateStruct":566,"startDateStruct":568,"completionDateStruct":570,"leadSponsor":572,"locationsCount":361},"100561979","phase-4-evaluate-the-efficacy-and-safety-of-amino-acid-15-peritoneal-dialysis-solution-in-peritoneal-dialysis-patients-with-malnutrition-100561979","NCT06597201","Evaluate the Efficacy and Safety of Amino Acid (15) Peritoneal Dialysis Solution in Peritoneal Dialysis Patients with Malnutrition.","Multicenter, Prospective, Open-label, Randomized, Parallel-group Clinical Trial to Evaluate the Efficacy and Safety of Amino Acid (15) Peritoneal Dialysis Solution in Peritoneal Dialysis Patients with Malnutrition.","Inclusion Criteria:\n\n1. 18 to 75 years of age (including 18 and 75 years of age), regardless of sex;\n2. Stable CAPD patients treated with peritoneal dialysis for greater than or equal to 3 months;\n3. 25 ≤ serum ALB ≤ 40 g\u002FL on two consecutive occasions prior to enrollment (two occasions one week apart);\n4. Blood potassium ≥ 3.5 mmol\u002FL\n5. C-reactive protein (CRP) ≤ 2 x upper limit of normal (ULN);\n6. Carbon dioxide binding capacity \\>18 mmol\u002FL;\n7. Subjects voluntarily sign an informed consent form in writing prior to the commencement of any procedures related to the study, fully understand the purpose and significance of the trial, and are willing to comply with the trial protocol.\n\nExclusion Criteria:\n\n1. Within the past 3 months prior to the screening period, there has been a history of peritonitis, other infections, or inflammatory diseases, with hospitalization records;\n2. The possibility of receiving a kidney transplant during the study period;\n3. Patients with inadequate dialysis and screening period kt\u002Fv\\\u003C1.4;\n4. Patients with hemoglobin less than 80g\u002FL during the screening period;\n5. Patients who have used amino acid (15) peritoneal dialysate within 6 months prior to the screening period.\n6. Patients with bleeding events (active gastrointestinal hemorrhage, cerebral hemorrhage), cardiovascular and cerebrovascular events (cerebral infarction, myocardial infarction, etc., and NYHA grade ≥3 of cardiac function) within 30 days before screening period.\n7. In patients with active diarrhea during the screening period, as assessed by investigators, affecting nutrient absorption(Except for patients with chronic diarrhea, stool frequency \\\u003C 3 times\u002Fday);\n8. patients with contraindications to amino acid (15) peritoneal dialysis solutions: 1) hypersensitivity to any of the components of the product; 2) Serum urea level \\>38 mmol\u002Fl; 3) Presence of uremic symptoms such as marked loss of appetite, nausea and vomiting at the time of screening; 4) Various inborn abnormalities of amino acid metabolism; 5) hepatic insufficiency (active hepatitis); active hepatitis B or C, cirrhosis, active liver disease or positive seropositivity for human immunodeficiency virus (HIV) within 6 months prior to screening; 6) Uncorrectable mechanical defects that the investigator assesses as affecting efficacy or increasing the risk of infection; 7) History of loss of peritoneal function or impairment of peritoneal function due to extensive adhesions;\n9. Suffers from a malignant tumor or has a life expectancy of \\<6 months;\n10. Routine daily use of 4.25% glucose dialysis solution during the screening period;\n11. Diabetic subjects with poor prior glycemic control, e.g., HbAlc \\> 8%;\n12. Women during pregnancy or breastfeeding;\n13. Other circumstances that, in the opinion of the investigator, may make participation in this study inappropriate.",{"count":557,"type":21},400,[559],"PHASE4","This is a multicenter, randomized, parallel controlled Phase IV clinical study to evaluate the safety and efficacy of amino acid (15) peritoneal dialysis solution in patients undergoing peritoneal dialysis with malnutrition in CAPD patients undergoing peritoneal dialysis maintenance.",[29],[100,563,564],"peritoneal dialysis solution","malnutrition","2024-12-27",{"date":567,"type":38},"2024-12-30",{"date":569,"type":38},"2024-08-09",{"date":571,"type":21},"2025-06-29",{"name":573,"class":80},"Chengdu Qingshan Likang Pharmaceutical Co., Ltd",{"id":575,"slug":576,"hasResults":11,"nctId":577,"briefTitle":578,"officialTitle":579,"acronym":4,"eligibilityCriteria":580,"healthyVolunteers":11,"sex":16,"minAge":55,"maxAge":4,"enrollmentInfo":581,"targetDuration":4,"studyType":202,"phases":4,"briefSummary":583,"conditions":584,"keywords":4,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":585,"lastUpdatePostDateStruct":586,"startDateStruct":588,"completionDateStruct":590,"leadSponsor":592,"locationsCount":46},"100569594","kinesiophobia-pain-balance-quality-of-life-and-mental-status-in-hemodialysis-patients-100569594","NCT06696274","Kinesiophobia, Pain, Balance, Quality of Life and Mental Status in Hemodialysis Patients","Investigation of the Relationship Between Kinesiophobia and Pain, Balance, Quality of Life and Mental Status in Hemodialysis Patients","Inclusion Criteria:\n\n* Patients with end stage renal disease receiving hemodialysis\n* Receiving hemodialysis for more than 3 months\n* Being clinically stable\n* Volunteering to participate in this stud\n\nExclusion Criteria:\n\n-Having musculoskeletal disorders that may affect physical performance",{"count":582,"type":21},32,"The aim of our study was to investigate the relationship between kinesiophobia and pain, balance, physical performance, quality of life and mental status in patients receiving hemodialysis.",[186,29],"2024-11-22",{"date":587,"type":38},"2024-11-25",{"date":589,"type":38},"2024-11-18",{"date":591,"type":21},"2026-01",{"name":593,"class":45},"Kirsehir Ahi Evran Universitesi","End-Stage Renal Disease (ESRD)"]